Seattle Genetics CEO Clay Siegall’s comp package soars to $18.1M, rivaling Big Pharma chiefs

After taking shareholders on something of a roller coaster ride last year, Seattle Genetics CEO Clay Siegall rewarded himself with a compensation package that swelled to more than twice the size of his financial reward for 2017.

Clay Siegall

Adding significantly to his columns on stock awards and options, Siegall’s compensation soared to $18.1 million last year, up from $8.6 million in 2017 and the $9.5 million package he garnered the year before that. That put his compensation at a multiple of 91 over the average salary at Seattle Genetics.

Merck vet Roger Dansey, the CMO who joined the company in May, rang up close to $10 million in compensation. CFO Todd Simpson, meanwhile, bagged $4.4 million in compensation, up from $3 million.

Seattle Genetics’ stock gained overall over the course of the year as the company captured its 5th OK for Adcetris, beefed up the pipeline and pushed its second armed antibody — enfortumab vedotin — to the FDA finish line.

Those income numbers put Siegall in the middle of the pack of compensation totals we’ve been tracking, with his packet adding up to a bigger figure than Eli Lilly CEO Dave Ricks ($17.2 million), or AstraZeneca chief Pascal Soriot ($14.8 million) — two companies which have a market cap way ahead of $SGEN. It’s also way above what Emma Walmsley garnered, still at the bottom of the chart with $7.7 million in compensation.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->